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1426 Methylene blue: The drug of choice for catecholamine-refractory vasoplegia
after cardiopulmonary bypass?
Rainer G. Leyh, MD, Theo Kofidis, MD, Martin Stru¨ber, MD, Stefan Fischer, MD, MSc,
Karsten Knobloch, MD, Bjoern Wachsmann, MS, Christian Hagl, MD, Andre R. Simon, MD,
and Axel Haverich, MD, Hannover, Germany
The guanylate cyclase inhibitor methylene blue was administered to 54 patients with
norepinephrine-refractory vasoplegia after cardiopulmonary bypass support. Immediately after
methylene blue infusion, an increase in mean systemic blood pressure, a clinically significant
increase in systemic vascular resistance, and a significant decrease in norepinephrine dosage
were seen in 92.4% of patients.
1432 No benefit of intraoperative whole blood sequestration and autotransfusion
during coronary artery bypass grafting: Results of a randomized clinical
trial
A. N. Ramnath, MD, H. R. Naber, MD, A. de Boer, MD, PhD, and J. A. Leusink, MD, PhD,
Nieuwegein and Utrecht, The Netherlands
In a randomized clinical trial concerning 148 patients, we evaluated the effect of heparin and
citrate intraoperative whole blood sequestration on the postoperative blood loss and use of
allogeneic blood products.
1438 Adverse effects of low hematocrit during cardiopulmonary bypass in the
adult: Should current practice be changed?
Robert H. Habib, PhD, Anoar Zacharias, MD, Thomas A. Schwann, MD, Christopher J.
Riordan, MD, Samuel J. Durham, MD, and Aamir Shah, MD, Toledo and Maumee, Ohio
We analyzed outcomes from 5000 cardiopulmonary bypass patients in terms of nadir on-pump
hematocrit. All major complications were systematically and significantly increased for
hematocrits 22% leading to greater hospital stays and death. Multivariate analysis showed
that increased hemodilution severity is associated with worse operative outcomes and decreased
0 to 6-year survival. Therefore, avoiding hematocrits below 20% to 22% during bypass may
potentially decrease the risks of postoperative vital organ dysfunction and of increased resource
utilization and short-intermediate term mortality.
1451 Embolic material generated by multiple aortic crossclamping: A perfusion
model with human cadaveric aorta f
Patrik Boivie, BS, Magnus Hansson, MD, PhD, and Karl Gunnar Engstro¨m, MD, PhD, FRCS,
Umeå, Sweden
A possible mechanism for crossclamp injury of the aorta was addressed. Ten human cadaveric
aortas were crossclamped sequentially and the washouts were analyzed by computerized image
processing. Repeated crossclamping produced substantial particle output. The number of
particles decreased after 5 clamp maneuvers. The results demonstrate hazards with repeated
aortic crossclamping.
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1461 Blocking the development of postischemic cardiomyopathy with viral gene
transfer of the apoptosis repressor with caspase recruitment domain
Subhasis Chatterjee, MD, Lawrence T. Bish, BA, Vasant Jayasankar, MD, Allan S. Stewart,
MD, Y. Joseph Woo, MD, Michael T. Crow, PhD, Timothy J. Gardner, MD, and H. Lee
Sweeney, PhD, Philadelphia, Pa, and Baltimore, Md
Apoptosis caused by acute ischemia and ventricular remodeling is implicated as a mediator of
heart failure. In a rabbit model of regional ischemia, viral gene transfer of ARC blocked
apoptosis, preserving ventricular geometry and function 6 weeks after infarction. ARC offers a
strategy to prevent late postischemic cardiomyopathy.
1470 Direct cell-cell interaction of cardiomyocytes is key for bone marrow stromal
cells to go into cardiac lineage in vitro
Shinya Fukuhara, MD, Shinji Tomita, MD, PhD, Seiji Yamashiro, MD, MSc, Takayuki
Morisaki, MD, PhD, Chikao Yutani, MD, PhD, Soichiro Kitamura, MD, PhD, and Takeshi
Nakatani, MD, PhD, Osaka and Saga, Japan
The present study provides the first demonstration, to our knowledge, of the cardiomyogenic
differentiation in bone marrow stromal cells without any chemicals in vitro. Direct cell-cell
interaction with cardiomyocytes was important for bone marrow stromal cells to differentiate
into cardiomyocytes.
1481 Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and
valdecoxib in patients undergoing coronary artery bypass surgery
Elisabeth Ott, MD, Nancy A. Nussmeier, MD, Peter C. Duke, MD, Robert O. Feneck, MD,
R. Peter Alston, MD, Michael C. Snabes, MD, PhD, Richard C. Hubbard, MD, Ping H. Hsu,
PhD, Lawrence J. Saidman, MD, and Dennis T. Mangano, PhD, MD, for the Multicenter Study
of Perioperative Ischemia (McSPI) Research Group and the Ischemia Research and Education
Foundation (IREF) Investigators, San Francisco, Calif; Munich, Germany; Houston, Tex;
Winnipeg, Canada; London, United Kingdom; Edinburgh, Scotland, United Kingdom; Stanford,
Calif; and Skokie, Ill
The COX-2 inhibitors parecoxib and valdecoxib are more effective as analgesics than a
regimen based on acetaminophen and opioids alone. However, in this trial their use was
associated with a doubling of serious adverse effects, including sternal wound infections,
raising important concerns and requiring comprehensive evaluation in a large-scale trial before
these COX-2 inhibitors are used in patients undergoing CABG.
1493 Technetium 99m-labeled tetrofosmin and iodine 123-labeled
metaiodobenzylguanidine scintigraphy in the assessment of transmyocardial
laser revascularization
Africa Muxı´, MD, Jordi Magrin˜a´, MD, Francisco Martı´n, MD, Miguel Josa, MD, David Fuster,
MD, Francisco J. Setoain, MD, Fe´lix Pe´rez-Villa, MD, Javier Pavı´a, PhD, and Xavier Bosch,
MD, Barcelona, Spain
A 99mTc-tetrofosmin stress-rest tomographic scan and 123I-MIBG planar scans were performed
before and after (3 and 12 months) transmyocardial laser revascularization (TMR) in 16
patients to evaluate myocardial perfusion and innervation. The TMR mechanism involves
perfusion improvement and denervation, mainly at 3 months, that partially recover at 12
months.
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1499 Sodium-hydrogen exchange inhibition preserves ventricular function after
ventricular fibrillation in the intact swine heart
David G. Rabkin, MD, Santos E. Cabreriza, MBA, Jared C. LaCorte, MD, Alan D. Weinberg,
MS, Lindita C¸oku, MD, Rowan Walsh, MD, Ralph Mosca, MD, and Henry M. Spotnitz, MD,
New York, NY
Sodium-hydrogen ion exchange inhibition attenuates ventricular dysfunction after 75 seconds of
VF and 40 minutes of reperfusion in the intact porcine heart. Further studies are warranted to
evaluate the potential use of this family of agents in conjunction with induction of VF for ICD
testing.
1510 Localization of nitric oxide synthase type III in the internal thoracic and
radial arteries and the great saphenous vein: A comparative
immunohistochemical study
Mario Gaudino, MD, Amelia Toesca, Bsc, Nicola Maggiano, Bsc, Claudio Pragliola, MD, and
Gianfederico Possati, MD, Rome, Italy
The NOS III distribution in the wall of human internal thoracic and radial artery and the great
saphenous vein was investigated by immunohistochemistry. NOS III was expressed in the
intima of all conduits and, unexpectedly, in the muscle cells of the media of muscular internal
thoracic arteries and radial arteries.
1516 Reactive hyperemia during early reperfusion as a determinant of improved
functional recovery in ischemic preconditioned rat hearts
Annie Rochetaing, PhD, and Paul Kreher, PhD, Angers, France
Ischemic preconditioning improved reactive hyperemia at reperfusion and contractile recovery.
Restricting this coronary peak flow forcibly or with L-NAME impaired recovery. Despite the
presence of L-NAME, forcibly reperfusing to 150% of baseline restored a high contractile
function. Therefore, reactive hyperemia at reperfusion is necessary for the mediation phase of
preconditioning.
Brief Communications 1526 Aortic valve replacement in the conscious patient under regional anesthesia
without endotracheal intubation
Thomas Schachner, MD, Johannes Bonatti, MD, Doris Balogh, MD, Josef Margreiter, MD,
Peter Mair, MD, Gu¨nther Laufer, MD, and Gu¨nther Putz, MD, Innsbruck, Austria
1528 Current indications for elective surgical treatment of dilated ascending
aorta: A new formula
Riccardo Codecasa, MD, Massimo A. Mariani, MD, PhD, Alessandro D’Alfonso, MD, Carmela
Nardi, MD, and Jan G. Grandjean, MD, PhD, Pisa, Italy
1531 Accessory mitral valve as cause of left ventricular obstruction in the adult
Joa˜o Costa, MD, Jorge Almeida, MD, Fernando Barreiros, MD, and Rodrigues Sousa, MD,
Porto, Portugal
1533 Exposure of the coronary artery using an ultrasonic scalpel
Shoichi Takahashi, MD, Ikuo Fukuda, MD, Toshihiko Kuga, MD, and Masanori Tanaka, PhD,
MD, Hirosaki, Japan
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1535 A simple method of intraoperative preparation of a stent graft for distal
aortic arch aneurysm
Ryuji Kunitomo, MD, Shigeyuki Tsurusaki, MD, Hisashi Sakaguchi, MD, Ichiro Ideta, MD,
Kentaro Takaji, MD, Yukihiro Katayama, MD, and Michio Kawasuji, MD, Kumamoto, Japan
1537 Video-assisted transseptal cryoablation of left atrium in nonmitral cases
Toshiya Ohtsuka, MD, Hiroshi Kubota, MD, Yoshihiro Suematsu, MD, Noboru Motomura, MD,
and Shinichi Takamoto, MD, Tokyo, Japan
1539 Maze procedure in the Marfan syndrome
Hiroyuki Nakajima, MD, Ko Bando, MD, Soichiro Kitamura, MD, Junjiro Kobayashi, MD,
Kazuo Niwaya, MD, and Osamu Tagusari, MD, Osaka, Japan
1541 Stent graft placement of the thoracoabdominal aorta in a patient with
Marfan syndrome
Tatjana M. Fleck, MD, Doris Hutschala, MD, Heinz Tschernich, MD, Erwin Rieder, MD,
Martin Czerny, MD, Ernst Wolner, MD, and Martin Grabenwoger, MD, Vienna, Austria
1544 Acute stent thrombosis after off-pump coronary bypass surgery: A new and
avoidable complication?
J. M. Alvarez, FRACS, L. Chen, MB, BS, and I. N. Sinclair, FRACP, Perth, West Australia
1546 Proximal prolapse of aortic intimal flap: A rare complication of acute type
A aortic dissection
G. Hossein Almassi, MD, Milwaukee, Wis
1548 Flap suffocation: An uncommon mechanism of coronary malperfusion in
acute type A dissection
Massimo Massetti, MD, Eugenio Neri, MD, Gerard Babatasi, MD, Olivier Le Page, MD, Remı´
Sabatier, MD, Dimitrios Buklas, MD, Gilles Grollier, MD, and Andre´ Khayat, MD, Caen,
France, and Siena, Italy
1550 The frozen elephant trunk technique: A new treatment for thoracic aortic
aneurysms
Matthias Karck, MD, Ajay Chavan, MD, Christian Hagl, MD, Holger Friedrich, MD, Michael
Galanski, MD, and Axel Haverich, MD, Hannover, Germany
1553 Mitral valve–sparing operation in subaortic stenosis caused by anomalous
papillary muscle and discrete subaortic stenosis
Jen-Ping Chang, MD, Hung-I Lu, MD, Chiung-Lun Kao, MD, and Teng-Hung Yu, MD,
Taiwan, Republic of China
1556 Complete augmentation of diffuse narrowing of the aorta with Williams
syndrome by using an overturn approach
Masaaki Yamagishi, MD, Keisuke Shuntoh, MD, Tsutomu Matsushita, MD, Katsuji Fujiwara,
MD, Takeshi Shinkawa, MD, Takako Miyazaki, MD, and Nobuo Kitamura, MD, Kyoto, Japan
1559 Platypnea-orthodeoxia in a patient after atrial switch operation for
transposition of the great arteries: Case report
Hildegard Tanner, MD, Beat Walder, MD, Beat Kipfer, MD, Christian Seiler, MD, Dieter
Wallmann, MD, Thierry Carrel, MD, Paul Mohacsi, MD, and Roger Hullin, MD, Bern,
Switzerland
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